Boston Scientific (NYSE: BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes.
A 32-Year-Old’s Startup, Inspired By A Health Scare, Sells For $275 Million
Surbhi Sarna was 13 and working on a school assignment in her bedroom when she felt a pain in her side so severe she blacked out. It was a complex ovarian cyst, doctors told her. What they couldn’t tell her at first: whether or not it was cancer. (It wasn’t.)